Tempus AI Taps Rare Cancer Data to Power Its Next Precision Oncology Push

Tempus AI (NASDAQ: TEM) just added another rare‑disease data asset to its oncology flywheel, and the stock inched higher on the news. Shares rose about 6.5% after Tempus announced a research collaboration with Angiosarcoma Awareness, Inc. to deepen data‑driven research in angiosarcoma, a rare and aggressive cancer with limited treatment options.

What Tempus AI and Angiosarcoma Awareness are doing

Tempus will contribute roughly 600 de‑identified angiosarcoma patient records, each with paired DNA and RNA sequencing plus associated clinical data where available. That single move creates one of the largest known disease‑specific molecular datasets in angiosarcoma, a huge upgrade from the tiny, fragmented datasets that usually exist in ultra‑rare cancers.

Angiosarcoma Awareness, Inc. will use this dataset alongside Tempus’ analytical tools to study the biology of angiosarcoma, look for new targets and signatures, and potentially identify subgroups that respond differently to therapies. The collaboration builds directly on the Angiosarcoma Project, launched in 2017 with the Broad Institute of MIT and Harvard, Dana‑Farber Cancer Institute and Count Me In to crowd‑source data and samples from patients and families.

Why this matters for TEM’s strategy

Tempus AI’s core pitch is that its de‑identified multimodal datasets and analytics can accelerate precision medicine across both common and rare cancers. By structuring and expanding a high‑quality dataset in a cancer as rare as angiosarcoma, Tempus reinforces that it is not just chasing big, high‑prevalence indications, but also positioning itself as the go‑to data partner in neglected diseases where traditional biopharma struggles to find enough patients.

The angiosarcoma partnership follows other high‑profile collaborations — from AstraZeneca (AZN) and Pathos AI on a $200 million multimodal oncology foundation model, to Gilead (GILD), ARPA‑H’s ADAPT cancer program, and Blood Cancer United in pediatric AML. Each deal adds another spoke to the same wheel: more data, more AI‑enabled insight, and a deeper role in clinical research infrastructure.

Investor angle

For now, the angiosarcoma collaboration is more strategic than financial; Tempus did not disclose economics, and this is not on the scale of the AstraZeneca or ARPA‑H agreements. But it extends the company’s footprint in rare cancers, where strong datasets can be uniquely valuable for biopharma partners and future foundation models.finance.

The stock is still down about 22% year to date, and execution against Tempus’ ambitious growth and profitability targets remains the main swing factor. However, partnerships like this one support the long‑term thesis that TEM is building a differentiated oncology data and AI platform spanning both blockbuster and ultra‑rare indications.